Tolerability of olaparib monotherapy versus chemotherapy in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD.
Authors
Domchek, SRobson, M
Im, S
Senkus, E
Xu, B
Masuda, N
Delaloge, S
Li, W
Armstrong, Anne C
Conte, P
Bannister, W
Goessl, C
Runswick, S
Goel, S
Tung, N
Affiliation
Basser Center, University of Pennsylvania, Philadelphia, PAIssue Date
2018-02-14
Metadata
Show full item recordCitation
Tolerability of olaparib monotherapy versus chemotherapy in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD. 2018, 78(4 Suppl): P5-21-12 Cancer ResJournal
Cancer ResearchDOI
10.1158/1538-7445.SABCS17-P5-21-12Type
Meetings and ProceedingsLanguage
enISSN
0008-54721538-7445
ae974a485f413a2113503eed53cd6c53
10.1158/1538-7445.SABCS17-P5-21-12